BR0014420A - Composição farmacêutica, método para a preparação de uma composição farmacêutica, e, kit para preparar uma composição farmacêutica aquosa - Google Patents

Composição farmacêutica, método para a preparação de uma composição farmacêutica, e, kit para preparar uma composição farmacêutica aquosa

Info

Publication number
BR0014420A
BR0014420A BR0014420-7A BR0014420A BR0014420A BR 0014420 A BR0014420 A BR 0014420A BR 0014420 A BR0014420 A BR 0014420A BR 0014420 A BR0014420 A BR 0014420A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
preparing
kit
aqueous
composition
Prior art date
Application number
BR0014420-7A
Other languages
English (en)
Inventor
Brent S Kendrick
Brian Peterson
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of BR0014420A publication Critical patent/BR0014420A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA, MéTODO PARA A PREPARAçãO DE UMA COMPOSIçãO FARMACêUTICA, E, KIT PARA PREPARAR UMA COMPOSIçãO FARMACêUTICA AQUOSA". Composições congeladas e liofilizadas para um agente fibrinolítico de metaloproteinase (fibrolase ou, NAT), um método para preparar a composição liofilizada, e um kit e um método para reconstituir a composição liofilizada são aqui descritos.
BR0014420-7A 1999-10-01 2000-09-29 Composição farmacêutica, método para a preparação de uma composição farmacêutica, e, kit para preparar uma composição farmacêutica aquosa BR0014420A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/411,335 US6440414B1 (en) 1999-10-01 1999-10-01 Pharmaceutical compositions of fibrinolytic agent
PCT/US2000/027022 WO2001024817A2 (en) 1999-10-01 2000-09-29 Pharmaceutical compositions of fibrinolytic agent

Publications (1)

Publication Number Publication Date
BR0014420A true BR0014420A (pt) 2002-06-11

Family

ID=23628514

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0014420-7A BR0014420A (pt) 1999-10-01 2000-09-29 Composição farmacêutica, método para a preparação de uma composição farmacêutica, e, kit para preparar uma composição farmacêutica aquosa

Country Status (28)

Country Link
US (4) US6440414B1 (pt)
EP (2) EP1438967A3 (pt)
JP (1) JP2003510369A (pt)
KR (1) KR100717435B1 (pt)
CN (2) CN101209347A (pt)
AT (1) ATE262923T1 (pt)
AU (1) AU769313B2 (pt)
BG (1) BG106578A (pt)
BR (1) BR0014420A (pt)
CA (1) CA2385966A1 (pt)
CZ (1) CZ20021033A3 (pt)
DE (2) DE60009529T2 (pt)
DK (1) DK1220685T3 (pt)
EA (2) EA004627B1 (pt)
ES (2) ES2218228T3 (pt)
HK (1) HK1049112B (pt)
HU (1) HUP0202654A3 (pt)
IL (1) IL148842A0 (pt)
MX (1) MXPA02003197A (pt)
NO (1) NO20021500L (pt)
NZ (4) NZ540967A (pt)
PL (1) PL355016A1 (pt)
PT (1) PT1220685E (pt)
SG (1) SG148823A1 (pt)
SK (1) SK4242002A3 (pt)
WO (1) WO2001024817A2 (pt)
YU (1) YU23302A (pt)
ZA (1) ZA200202400B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2921180B1 (en) 1999-02-22 2019-08-14 University of Connecticut Albumin-free factor VIII formulations
US6440414B1 (en) 1999-10-01 2002-08-27 Amgen Inc. Pharmaceutical compositions of fibrinolytic agent
US6261820B1 (en) 1999-10-01 2001-07-17 Amgen Inc. Fibronolytically active polypeptide
US6455269B1 (en) 1999-12-17 2002-09-24 Amgen, Inc. Method for localized administration of fibrinolytic metalloproteinases
US7033776B2 (en) 1999-12-17 2006-04-25 Amgen Inc. Method for treatment of indwelling catheter occlusion using fibrinolytic metalloproteinases
DE10149030A1 (de) * 2001-10-05 2003-04-10 Viscum Ag Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
BR0307518A (pt) * 2002-02-01 2004-12-28 Shimoda Biotech Pty Ltd Composição farmacêutica
CA2472956A1 (en) * 2002-02-14 2003-08-21 Bayer Pharmaceuticals Corporation Formulation strategies in stabilizing peptides in organic solvents and in dried states
US6803046B2 (en) * 2002-08-16 2004-10-12 Bracco International B.V. Sincalide formulations
US8304387B2 (en) * 2004-12-15 2012-11-06 Swedish Orphan Biovitrum Ab (Publ) Therapeutic formulations of keratinocyte growth factor
AU2006316005A1 (en) * 2005-11-18 2007-05-24 Eisai R & D Management Co., Ltd. Process for production of cinnamamide derivative
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
US7867747B2 (en) * 2006-11-08 2011-01-11 Korea Ocean Research And Development Institute Fibrinolytic metalloprotease and composition comprising the same
EP1958618A1 (de) 2007-02-15 2008-08-20 Octapharma AG Verfahren zur Gefriertrocknung mit optimierter Rekonstitution von Biopolymeren
NZ593190A (en) 2008-11-07 2013-01-25 Baxter Int Factor viii formulations
WO2011004011A1 (en) * 2009-07-10 2011-01-13 Thrombogenics Nv Variants of plasminogen and plasmin
CN102000022A (zh) * 2010-11-23 2011-04-06 郑州大学 注射用重组双功能纤溶酶冻干制剂及其制备方法
JP6085568B2 (ja) 2011-01-05 2017-02-22 スロンボジェニックス・ナムローゼ・フェンノートシャップＴｈｒｏｍｂｏＧｅｎｉｃｓ ＮＶ プラスミノーゲンおよびプラスミンの変異体
US9644196B2 (en) 2011-08-12 2017-05-09 Thrombogenics Nv Plasminogen and plasmin variants
US20140212405A1 (en) 2013-01-28 2014-07-31 2294719 Ontario Limited Fibrinolytic/Proteolytic Treatment of Myofacial and Neuropathic Pain and Related Conditions
CN107250375A (zh) * 2014-11-06 2017-10-13 科罗拉多州立大学董事会 在血栓溶解剂存在下使用粘弹性分析鉴定新疾病状态
US20220305094A1 (en) * 2019-01-06 2022-09-29 Endo Global Aesthetics Limited Collagenase formulations and methods of producing the same

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2310133A2 (fr) 1975-05-05 1976-12-03 Fabre Sa Pierre Nouveau medicament comportant un activateur du plasminogene perfectionne
JPS57500844A (pt) * 1980-06-27 1982-05-13
US4447236A (en) 1982-02-05 1984-05-08 Cordis Corporation Infusion catheter system
US4610879A (en) 1984-01-06 1986-09-09 University Of Southern California Fibrinolytic enzyme from snake vernom
CA1237482A (en) 1984-03-09 1988-05-31 Frank B. Stiles Catheter for effecting removal of obstructions from a biological duct
US4755167A (en) 1984-04-10 1988-07-05 Research Corporation In vivo method for distribution and stirring of therapeutic agents
US4837148A (en) 1984-10-30 1989-06-06 Phillips Petroleum Company Autonomous replication sequences for yeast strains of the genus pichia
US4885242A (en) 1984-10-30 1989-12-05 Phillips Petroleum Company Genes from pichia histidine pathway and uses thereof
US4855231A (en) 1984-10-30 1989-08-08 Phillips Petroleum Company Regulatory region for heterologous gene expression in yeast
US4818700A (en) 1985-10-25 1989-04-04 Phillips Petroleum Company Pichia pastoris argininosuccinate lyase gene and uses thereof
US4812405A (en) 1986-02-18 1989-03-14 Phillips Petroleum Company Double auxotrophic mutants of Pichia pastoris and methods for preparation
US5000185A (en) 1986-02-28 1991-03-19 Cardiovascular Imaging Systems, Inc. Method for intravascular two-dimensional ultrasonography and recanalization
US4848700A (en) * 1987-04-16 1989-07-18 Lockheed John A Canard control system for aircraft
ZA889415B (en) 1987-12-18 1989-09-27 Chiron Corp Compositions and method for recombinant production of crotalidus venum fibrolase
WO1990007352A1 (en) 1989-01-04 1990-07-12 Boston Scientific Corporation Angioplasty catheter
US5222941A (en) 1990-01-12 1993-06-29 Don Michael T Anthony Method of dissolving an obstruction in a vessel
DE69133066T2 (de) 1990-01-16 2003-03-06 Centro De Ingenieria Genetica Y Biotecnologia, Cubanacan Playa Verfahren zur Expression heterologischer Gene in der Hefe Pichia Pastoris, Expressionsverfahren und transformierte Mikroorganismen
US5709676A (en) 1990-02-14 1998-01-20 Alt; Eckhard Synergistic treatment of stenosed blood vessels using shock waves and dissolving medication
US5250034A (en) 1990-09-17 1993-10-05 E-Z-Em, Inc. Pressure responsive valve catheter
US5167628A (en) 1991-05-02 1992-12-01 Boyles Paul W Aortic balloon catheter assembly for indirect infusion of the coronary arteries
US5380273A (en) 1992-05-19 1995-01-10 Dubrul; Will R. Vibrating catheter
EP0624642B1 (en) 1993-05-12 1999-01-20 Indian Council For Medical Research Novel thrombolytic agent, process for preparing same and its use for the preparation of a thrombi dissolving medicament
US5370653A (en) 1993-07-22 1994-12-06 Micro Therapeutics, Inc. Thrombectomy method and apparatus
JP3537440B2 (ja) 1993-12-17 2004-06-14 持田製薬株式会社 可溶性トロンボモジュリンを長期保存安定化させる方法
US5626564A (en) 1995-03-31 1997-05-06 Creighton University Adjustable sideholes catheter
US5830468A (en) 1995-05-17 1998-11-03 The New York Blood Center, Inc. Fibrin(ogen) degradation by fibrinolytic matrix metalloproteinase
US6020181A (en) 1995-05-17 2000-02-01 New York Blood, Inc. Inhibition of thrombus formation by medical related apparatus comprising treating with fibrinolytic matrix metalloproteinase
US5741779A (en) 1996-05-10 1998-04-21 Xoma Corporation Antithrombotic materials and methods
KR20000015944A (ko) 1996-05-24 2000-03-15 팜 윌리암 엔. 신체 통로의 질병을 치료 또는 예방하기 위한조성물 및 방법
US5951981A (en) 1996-12-02 1999-09-14 Diatide, Inc. Thrombolytic agents with antithrombotic activity
US6413760B1 (en) 1997-04-15 2002-07-02 Genetics Institute, Inc. Highly purified mocarhagin cobra venom protease polynucleotides endcoding same and related proteases and therapeutic uses thereof
US6261820B1 (en) 1999-10-01 2001-07-17 Amgen Inc. Fibronolytically active polypeptide
US6440414B1 (en) 1999-10-01 2002-08-27 Amgen Inc. Pharmaceutical compositions of fibrinolytic agent
US6455269B1 (en) 1999-12-17 2002-09-24 Amgen, Inc. Method for localized administration of fibrinolytic metalloproteinases
US20020081685A1 (en) 2000-08-03 2002-06-27 Fox Brian A. Disintegrin homologs, ZSNK10, ZSNK11, and ZSNK12

Also Published As

Publication number Publication date
ZA200202400B (en) 2003-05-28
ATE262923T1 (de) 2004-04-15
EP1438967A3 (en) 2005-01-26
DE04007657T1 (de) 2005-01-13
US20060263347A1 (en) 2006-11-23
SK4242002A3 (en) 2003-08-05
AU769313B2 (en) 2004-01-22
NZ550200A (en) 2008-04-30
HUP0202654A2 (hu) 2002-12-28
CN101209347A (zh) 2008-07-02
EA006600B1 (ru) 2006-02-24
NO20021500D0 (no) 2002-03-26
WO2001024817A3 (en) 2001-10-18
CN100353999C (zh) 2007-12-12
NZ518007A (en) 2004-03-26
IL148842A0 (en) 2002-09-12
PT1220685E (pt) 2004-08-31
EA200400182A1 (ru) 2004-08-26
MXPA02003197A (es) 2002-09-30
BG106578A (bg) 2003-04-30
CN1402641A (zh) 2003-03-12
NZ540967A (en) 2007-02-23
WO2001024817A2 (en) 2001-04-12
ES2218228T3 (es) 2004-11-16
DK1220685T3 (da) 2004-08-02
HK1049112A1 (en) 2003-05-02
SG148823A1 (en) 2009-01-29
US7311908B2 (en) 2007-12-25
HUP0202654A3 (en) 2003-11-28
EP1220685B1 (en) 2004-03-31
CZ20021033A3 (cs) 2003-06-18
DE60009529T2 (de) 2005-04-14
KR100717435B1 (ko) 2007-05-14
EA004627B1 (ru) 2004-06-24
YU23302A (sh) 2005-06-10
PL355016A1 (en) 2004-03-22
US20020192207A1 (en) 2002-12-19
NZ530959A (en) 2005-08-26
US6440414B1 (en) 2002-08-27
EP1438967A2 (en) 2004-07-21
EP1220685A2 (en) 2002-07-10
US20060246053A1 (en) 2006-11-02
US7244426B2 (en) 2007-07-17
JP2003510369A (ja) 2003-03-18
NO20021500L (no) 2002-05-27
EA200200396A1 (ru) 2002-10-31
CA2385966A1 (en) 2001-04-12
US7138114B2 (en) 2006-11-21
DE60009529D1 (de) 2004-05-06
AU7743000A (en) 2001-05-10
ES2224917T1 (es) 2005-03-16
KR20020053065A (ko) 2002-07-04
HK1049112B (en) 2005-01-21

Similar Documents

Publication Publication Date Title
BR0014420A (pt) Composição farmacêutica, método para a preparação de uma composição farmacêutica, e, kit para preparar uma composição farmacêutica aquosa
FR2811552B1 (fr) Composition notamment cosmetique ou pharmaceutique se presentant sous forme solide
BR0315767A (pt) Composição imunogência, método para fabricar uma vacina, kit, vacina, recipiente com uma superfìcie interna repelente à água, e, método para preservar uma composição que compreende ipv e um agente estabilizador
DE69729786D1 (de) Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen
HRP20020880B1 (en) New pharmaceutical composition
BR0100046A (pt) Copolìmeros reticulados solúveis em água ou intumescìveis em água
BRPI0311877B8 (pt) formulação farmacêutica ácida de insulina com estabilidade aperfeiçoada
BR9806212A (pt) Composições farmacêuticas sólidas compreendendo uma ciclosporina e um surfactante aniÈnico.
EP1226109A4 (en) PHENYLAMINE CARBOXYLIC ACID COMPOUNDS AND COMPOSITIONS FOR DISPENSING ACTIVE AGENTS
ZA200500716B (en) Solid pharmaceutical composition containing a lipophilic active principle and preparation method thereof
BR0116587A (pt) Uso de uma eritropoietina, composição farmacêutica, métodos para proteger, manter ou realçar a viabilidade de uma célula, tecido ou órgão isolado de um corpo mamìfero, para facilitar a trancitose de uma molécula através de uma barreira endotelial celular em um mamìfero, composição para transportar uma molécula via trancitose através de uma barreira endotelial celular, e, composição
BR9704554B1 (pt) utilizaÇço de lipÍdios complexos como adiÇÕes de estabilizaÇço para composiÇÕes farmacÊuticas de misturas de enzimas de digestço, composiÇÕes farmacÊuticas soléveis em Água e kit para preparaÇço de soluÇÕes aquosas.
YU54499A (sh) Farmaceutski preparat za primenu na mukozu
NO20021859D0 (no) Nye digosakkarider, deres fremstilling samt farmasöytiske preparater
HUP9700826A1 (hu) Peptikus fekély elleni gyógyászati készítmények
DK0482097T3 (da) Tensidpræparater og fremgangsmåder
EP2017269A9 (en) A pharmaceutical composition comprising form II crystalline Ritonavir and a preparation thereof
JP2001525373A5 (pt)
DE60002719D1 (de) Ophthalmische zusammensetzungen in form wässriger gele
BR0204573A (pt) Composição para redução da irritação cutânea enzimática
ES2176786T3 (es) Uso de extractos de ginkgo biloba para la preparacion de composicionesfarmaceuticas.
UY27373A1 (es) Formulaciones de interferón beta-humano
DE69923835D1 (de) Makrolid-lhrh-antagonisten
HRP20020071B1 (hr) Farmaceutske kompozicije i pripravljanje istih
ATE291058T1 (de) Vernetzerfreie zubereitungen

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]